Your session is about to expire
← Back to Search
18F-NOS PET/CT Scan for Parkinson's Disease
Phase < 1
Waitlist Available
Led By Jacob Dubroff, MD
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Participants will be 18-75 years of age.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether a PET scan can help diagnose or monitor Parkinson's disease by measuring inflammation in the brain.
Who is the study for?
This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.
What is being tested?
The study tests a PET/CT scan using a tracer called 18F-NOS to detect brain inflammation, which could help diagnose or monitor Parkinson's disease treatment effectiveness.
What are the potential side effects?
While not explicitly listed, potential side effects may include discomfort from the injection of the tracer, allergic reactions to the imaging drug, and exposure to radiation from the PET/CT scan.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was diagnosed with Parkinson's Disease over 3 years ago.
Select...
I am between 18 and 75 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Characterize the uptake of [18F]NOS
Secondary study objectives
Compare patterns of uptake
Compare peripheral blood inflammatory biomarkers
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Patient with Parkinson DiseaseExperimental Treatment1 Intervention
Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.
Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Group II: Healthy ControlExperimental Treatment1 Intervention
Subject must be a Healthy.
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,073 Previous Clinical Trials
42,714,245 Total Patients Enrolled
Jacob Dubroff, MDPrincipal InvestigatorUniversity of Pennsylvania
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I was diagnosed with Parkinson's Disease over 3 years ago.I am capable of understanding and consenting to participate in the study.I am between 18 and 75 years old.
Research Study Groups:
This trial has the following groups:- Group 1: Patient with Parkinson Disease
- Group 2: Healthy Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger